異位性皮膚炎市場 - KOL的考察

本報告提供異位性皮膚炎市場相關調查分析，對已上市的治療方法和開發平台治療方法的未來性KOL考察。

目錄

摘要整理

異位性皮膚炎的未來的治療範例

調查目的

目前治療策略

• Dupixent (dupilumab; Sanofi/Regeneron)
  • 重要的考察的彙整
• Adbry/Adtralza (tralokinumab; LEO Pharma)
  • 重要的考察的彙整
• Olumiant (baricitinib; Lilly/Incyte)
  • 重要的考察的彙整
• Cibinqo (abrocitinib; Pfizer)
  • 重要的考察的彙整
• Rinvoq (upadacitinib; AbbVie)
  • 重要的考察的彙整

後期開發平台計劃

• Lebrikizumab (Lilly/Almirall)
  • 重要的考察的彙整
• Nemolizumab (Galderma/Chugai/Maruho)
  • 重要的考察的彙整
• Etrasimod (Pfizer)
  • 重要的考察的彙整
• Ivarmacitinib (SHR 0302; Reistone Biopharma)
  • 重要的考察的彙整
• Rocatinlimab (Kyowa Kirin/Amgen)
  • 重要的考察的彙整

對治療帶來影響的初期階段的開發與其他的因素

• 專家們對 B 244 作為異位性皮膚炎的潛在治療方法感到驚訝。 附錄

附錄

What clinical advantages underpin KOLs' opinion that Eli Lilly/Almirall's anti-IL13 lebrikizumab has the potential to disrupt the treatment paradigm and which current therapies could be impacted? Why are experts excited about Kyowa Kirin/Amgen's novel anti-OX40 rocatinlimab and where do they see it delivering value? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

Table of Contents

Executive summary (9)

Future treatment paradigm for atopic dermatitis

Research objectives (1)

Current treatment strategies (43)

• Dupixent (dupilumab; Sanofi/Regeneron) (10)
  • Key insights summary (10)
• Adbry/Adtralza (tralokinumab; LEO Pharma) (11)
  • Key insights summary (11)
• Olumiant (baricitinib; Lilly/Incyte) (8)
  • Key insights summary (8)
• Cibinqo (abrocitinib; Pfizer) (8)
  • Key insights summary (8)
• Rinvoq (upadacitinib; AbbVie) (6)
  • Key insights summary (6)

Late-stage pipeline programmes (34)

• Lebrikizumab (Lilly/Almirall) (6)
  • Key insights summary (6)
• Nemolizumab (Galderma/Chugai/Maruho) (6)
  • Key insights summary (6)
• Etrasimod (Pfizer) (7)
  • Key insights summary (7)
• Ivarmacitinib (SHR 0302; Reistone Biopharma) (6)
  • Key insights summary (6)
• Rocatinlimab (Kyowa Kirin/Amgen) (9)
  • Key insights summary (9)

Earlier-stage developments and other factors impacting treatment (12)

• Experts are underwhelmed by B 244 as a potential therapy for atopic dermatitis (11)
  • KOLs regard lirentelimab as interesting but question whether mast cells and eosinophils play a central role in atopic dermatitis (3)
  • LP 0145 has potential but some experts believe bispecific inhibition or selecting IL22-expressing population may hold more benefit (1)
  • Microbiome involvement in preventing atopic dermatitis is a formidable goal; KOLs agree very limited progress being made (2)
  • New topical formulations will be welcomed in the US; European KOLs are sceptical that they will reach the European market due to high cost (3)

Appendix (4)

• KOL details (4)
  • US KOLs (1)
  • European KOLs (2)